Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) expects annual dividend of $0.71

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) declared an annual dividend on Friday, April 29, the wall street journal reports. Shareholders of record on Monday, May 16 will receive a dividend of 0.7093 per share on Friday, May 27. This represents a return of 3.4%. The ex-dividend date is Friday, May 13.

Fresenius Medical Care AG & Co. KGaA has a payout ratio of 33.7%, meaning its dividend is sufficiently covered by earnings. Analysts expect Fresenius Medical Care AG & Co. KGaA to earn $2.34 per share next year, meaning the company should continue to be able to cover its $0.82 annual dividend. with an expected future payout ratio of 35.0%.

Shares of FMS opened at $30.93 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.82 and a debt ratio of 0.48. The stock has a market capitalization of $18.12 billion, a P/E ratio of 15.78, a PEG ratio of 1.42 and a beta of 1.20. The company has a 50-day moving average of $32.67 and a two-hundred-day moving average of $32.83. Fresenius Medical Care AG & Co. KGaA has a 12 month minimum of $28.75 and a 12 month maximum of $42.45.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last announced its results on Tuesday, February 22. The company reported earnings per share (EPS) of $0.51 for the quarter, beating analyst consensus estimates of $0.50 by $0.01. The company posted revenue of $5.31 billion in the quarter, versus $5.38 billion expected by analysts. Fresenius Medical Care AG & Co. KGaA achieved a net margin of 5.51% and a return on equity of 7.51%. As a group, analysts expect Fresenius Medical Care AG & Co. KGaA to post EPS of 2.08 for the current fiscal year.

A number of institutional investors and hedge funds have recently increased or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in Fresenius Medical Care AG & Co. KGaA by 39.1% during the fourth quarter. Wells Fargo & Company MN now owns 11,224 shares of the company worth $364,000 after purchasing 3,153 additional shares during the period. Forum Financial Management LP acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the fourth quarter for a value of approximately $295,000. Goldman Sachs Group Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 2.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 514,568 shares of the company worth $16,703,000 after purchasing an additional 14,491 shares during the period. Stifel Financial Corp increased its stake in Fresenius Medical Care AG & Co. KGaA by 14.0% during the fourth quarter. Stifel Financial Corp now owns 14,000 shares of the company worth $455,000 after purchasing an additional 1,722 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the fourth quarter for a value of approximately $419,000. Institutional investors hold 4.89% of the company’s shares.

FMS has been the subject of a number of research reports. Oddo Bhf upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and set a target price of €72.00 ($77.42) for the company in a research report of Tuesday, March 1. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “holding” rating to an “underperforming” rating and lowered its price target for the company from $32.40 to 30.30 $ in a research report from Friday, February 11. StockNews.com launched a hedge on shares of Fresenius Medical Care AG & Co. KGaA in a Thursday, March 31 research report. They issued a “buy” rating for the company. Societe Generale cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €61.00 ($65.59) to €57.00 ($61.29) in a Friday 25 research report february. To finish, Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating and set a price target of $35.00 for the company in a research report Tuesday, January 11. Two analysts gave the stock a sell rating, eight gave the company a hold rating and six gave the company a buy rating. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and a consensus price target of $51.71.

Fresenius Medical Care AG & Co. KGaA Company Profile (Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Featured articles

Dividend history for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.